AFFIMED NV (AFMD) Stock News
NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD
AFMD Latest News, Press Relases and Analysis
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode
The company has been granted an initial period of 180 calendar days, or until October 13, 2025, to regain compliance with Nasdaq’s Minimum Bid Price Rule.
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the...
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with...
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a...
Affimed Reports Third Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate...
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
MANNHEIM, Germany, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Present at the Cantor Global Healthcare Conference 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed Reports Second Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable...
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Appoints Shawn M. Leland as Chief Executive Officer
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - -...
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...